Program
anitocabtagene autoleucel
Also written as “Anitocabtagene Autoleucel”, “anitocabtagene-autoleucel” and “anito-cel”.
Its studies are mostly in Multiple Myeloma · Muscle Weakness, led by Gilead Sciences.
Furthest: phase 3, since May 9, 20246 company-led studies, 6 open or runningNext primary completion: Dec 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciences | 66 open or running | phase 3since May 9, 2024 | Oct 17, 2019 | Dec 2026phase 2 · NCT05396885 |
Also a collaborator on its studies: Arcellx.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 17, 2019First study: phase 1 study in RecurrenceFirst studyNCT04155749 · 40 enrolled · United States
- May 12, 2022Phase 2 study in Multiple MyelomaNCT05396885 · 136 enrolled · United States
- May 9, 2024Phase 3 study in Multiple MyelomaNCT06413498 · 452 enrolled · United States, Australia, Austria and more
- Sep 19, 2024Phase 1 study in Muscular DiseasesNCT06626919 · 30 planned · United States
- Oct 14, 20262 phase 3 studies in Multiple MyelomaNCT07903506, NCT07887672
- Oct 22, 2026Primary completion moved from 2027-03 to 2028-10Date moved laterphase 1 · +19 months · NCT06626919
Ahead
- Dec 2026Primary completion: phase 2 study in Multiple MyelomaNCT05396885
- Jul 2028Primary completion: phase 3 study in Multiple MyelomaNCT06413498
- Oct 2028Primary completion: phase 1 study in Muscular DiseasesNCT06626919
- Mar 2039Primary completion: phase 3 study in Multiple MyelomaNCT07903506
TargetBeta
TNFRSF17 →read by rule
“A preparation of autologous T-lymphocytes that are genetically modified ex vivo and transduced with a lentiviral vector to express a D-binding domain based chimeric antigen receptor (CAR) that specifically recognizes the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis ”NCIt, by rule
Other programs on TNFRSF17
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| elranatamabrule | Pfizer | phase 4 | 15 |
| linvoseltamabrule | Regeneron Pharmaceuticals | phase 4 | 13 |
| teclistamabrule | Johnson & Johnson | phase 4 | 11 |
| belantamab mafodotinrule | GlaxoSmithKline | phase 3 | 25 |
| Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F | AstraZeneca | phase 3 | 12 |
| etentamig | AbbVie | phase 3 | 11 |
| ramantamig | Johnson & Johnson | phase 3 | 7 |
| equecabtagene autoleucelrule | nanjing-iaso-biotechnology-co-ltd | phase 3 | 5 |
| Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934 | Sino Biopharmaceutical | phase 3 | 4 |
| GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003rule | Innovent Biologics | phase 3 | 4 |
| Evarucabgene Autoleucelrule | nexcella-inc | phase 3 | 2 |
| Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytesrule | cartesian-therapeutics | phase 2 | 6 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07903506Multiple Myeloma | 3 | Not yet recruiting | Mar 2039 | 750 |
| NCT07887672Multiple Myeloma | 3 | Not yet recruiting | Feb 2042 | 600 |
| NCT06626919Muscular Diseases · United States | 1 | Recruiting | Oct 2028 | 30 |
| NCT06413498Multiple Myeloma · United States, Australia, Austria and more | 3 | Active, not recruiting | Jul 2028 | 452 |
| NCT05396885Multiple Myeloma · United States | 2 | Active, not recruiting | Dec 2026 | 136 |
| NCT04155749Recurrence · United States | 1 | Active, not recruiting | Oct 3, 2024 | 40 |
How it is read
Names in the registry
- “Anitocabtagene Autoleucel”, 2 entries
- “anitocabtagene-autoleucel”, 2 entries
- “anito-cel”, 1 entry
- “Anitocabtagene autoleucel”, 1 entry
Conditions, from the studies’ own filings
- Multiple Myeloma, 5 studies
- Muscle Weakness, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.